Experimental aids vaccine now in production

Nov 12, 2008

(PhysOrg.com) -- The advance towards a vaccine for HIV/AIDS has taken another step closer to realization. A vaccine, developed by Dr. Chil-Yong Kang and his team at the Schulich School of Medicine & Dentistry at The University of Western Ontario, and licensed to Sumagen Canada Inc., has now been manufactured for use in trials - first, in toxicology trials using animal models and then in Phase 1 human clinical trials.
The vaccine has been manufactured at a bio-safety level 3 (BSL3) good manufacturing practice (GMP) facility in the United States.

“It has been very difficult to manufacture our genetically engineered HIV-1 experimental vaccine, because there are only a few BSL3 GMP contract manufacturing organizations (CMO) available in the world. For this reason, we welcome the Canadian Government’s plan to establish a BSL3 GMP facility in Canada for future manufacture of candidate HIV/AIDS vaccines. We have overcome a major hurdle in the development of our HIV/AIDS vaccine which is now ready for clinical trials,” said Dr. Dong Joon Kim, CEO of Sumagen.

The toxicology trials will get under way in a matter of days at a contract research organization (CRO) in the U.S., and results should be ready in approximately three months. The Phase 1 human clinical trials could begin in early spring at a number of trial sites in North America.

Kang's vaccine uses a killed whole HIV-1, much like Salk's killed whole poliovirus vaccine. The HIV-1 is genetically engineered in such a way that it is non-pathogenic and can be produced in large quantities. It is then purified, inactivated, and injected as a safe whole killed-virus vaccine.

While Phase 1 human clinical trials are most often conducted on healthy volunteers, in the case of this HIV/AIDS vaccine, it will be tested on individuals who are HIV-positive, but not yet symptomatic with AIDS.

More than 25 million people have died of AIDS since 1981 and approximately 35 million people live with HIV infection world-wide today.

Sumagen Canada Inc. is a subsidiary of Curocom of Korea. The company is fully funding Dr. Kang’s continuing work on the HIV/AIDS vaccine development.

Provided by University of Western Ontario

Explore further: Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum

add to favorites email to friend print save as pdf

Related Stories

Volunteers key to success of Thai vaccine trials

Sep 28, 2009

(AP) -- Nearly 16,000 Thais ignored the false rumors that they were being infected by the AIDS virus, and overcame their fears of becoming social outcasts to participate in the first HIV vaccine trials to ...

Recommended for you

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments : 0

More news stories

UAE reports 12 new cases of MERS

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

NASA's space station Robonaut finally getting legs

Robonaut, the first out-of-this-world humanoid, is finally getting its space legs. For three years, Robonaut has had to manage from the waist up. This new pair of legs means the experimental robot—now stuck ...